{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:43:47Z","timestamp":1793033027937,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014931","name":"Arrowhead Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014931","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017981","name":"Sysmex Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017981","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.molmed.2022.06.002","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T08:18:15Z","timestamp":1656490695000},"page":"742-757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["New strategies for the treatment of chronic hepatitis B"],"prefix":"10.1016","volume":"28","author":[{"given":"Lung-Yi","family":"Mak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Shing","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":false,"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2022.06.002_bb0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0010","series-title":"Global Hepatitis Report 2017","author":"WHO","year":"2017"},{"key":"10.1016\/j.molmed.2022.06.002_bb0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0020","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2022.06.002_bb0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0030","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.molmed.2022.06.002_bb0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0040","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/jvh.12211","article-title":"Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naive chronic hepatitis B patients","volume":"21","author":"Hara","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.molmed.2022.06.002_bb0045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jvh.13237","article-title":"A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance","volume":"27","author":"Ko","year":"2020","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.molmed.2022.06.002_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels","volume":"8","author":"Lam","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0055","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.23568","article-title":"Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2022.06.002_bb0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0065","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/hep.31030","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B \u2013 report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"71","author":"Cornberg","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2022.06.002_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07586","article-title":"Humanized virus-suppressing factor inhibits hepatitis B virus infection by targeting viral cell entry","volume":"7","author":"Miyakawa","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.molmed.2022.06.002_bb0075","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.molmed.2022.06.002_bb0080","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature02872","article-title":"Revealing the world of RNA interference","volume":"431","author":"Mello","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2022.06.002_bb0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0090","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/gutjnl-2020-323445","article-title":"Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment","volume":"71","author":"Yuen","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2022.06.002_bb0095","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2022.06.002_bb0100","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/hep.31920","article-title":"Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B","volume":"74","author":"Gane","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2022.06.002_bb0105","first-page":"S761","article-title":"Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T-cell activation markers. The International Liver Congress","volume":"75","author":"Paratala","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0110","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/14728222.2017.1397134","article-title":"Hepatitis B core protein as a therapeutic target","volume":"21","author":"Mak","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.molmed.2022.06.002_bb0115","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00836-20","article-title":"ATI-2173, a novel liver-targeted non-chain-terminating nucleotide for hepatitis B virus cure regimens","volume":"64","author":"Squires","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.molmed.2022.06.002_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2019.02.009","article-title":"Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15cells","volume":"164","author":"Blanchet","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.molmed.2022.06.002_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104853","article-title":"Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro","volume":"183","author":"Boulon","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.molmed.2022.06.002_bb0130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/acsinfecdis.8b00156","article-title":"REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection","volume":"5","author":"Vaillant","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.molmed.2022.06.002_bb0135","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2022.06.002_bb0140","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0145","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0150","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0168-8278(20)30572-9","article-title":"Targeting inhibitor of apoptosis proteins (IAPs) enhances intrahepatic antiviral immunity to clear hepatitis B virus infection in vivo. The International Liver Congress","volume":"73","author":"Zhang","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0155","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/hep.31527","article-title":"ImmTAV, a new immunotherapy targeting the source of HBV infection","volume":"72","author":"Bertoletti","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2022.06.002_bb0160","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0165","article-title":"Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study","volume":"3","author":"Ma","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.molmed.2022.06.002_bb0170","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2022.06.002_bb0175","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","article-title":"Efficacy of lenvervimab, a recombinant human immunoglobulin, in treatment of chronic hepatitis B virus infection","volume":"18","author":"Lee","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0180","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/jvh.13608","article-title":"Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study","volume":"28","author":"Erken","year":"2021","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.molmed.2022.06.002_bb0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.virusres.2017.01.003","article-title":"Advances with using CRISPR\/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus","volume":"244","author":"Moyo","year":"2018","journal-title":"Virus Res."},{"key":"10.1016\/j.molmed.2022.06.002_bb0190","first-page":"2169","article-title":"Engineered zinc-finger transcription factors inhibit the replication and transcription of HBV in vitro and in vivo","volume":"41","author":"Luo","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.molmed.2022.06.002_bb0195","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1128\/JVI.00366-08","article-title":"Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture","volume":"82","author":"Zimmerman","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0200","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3390\/v13071344","article-title":"Improved specificity and safety of anti-hepatitis B virus TALENs using obligate heterodimeric FokI nuclease domains","volume":"13","author":"Smith","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.molmed.2022.06.002_bb0205","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2022.06.002_bb0210","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.molmed.2022.06.002_bb0215","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","article-title":"Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR\/Cas RNA-guided DNA endonuclease","volume":"476","author":"Kennedy","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.molmed.2022.06.002_bb0220","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fcimb.2017.00091","article-title":"Removal of integrated hepatitis B virus DNA using CRISPR-Cas9","volume":"7","author":"Li","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0225","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003131","article-title":"Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach","volume":"9","author":"Schiffer","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.590989","article-title":"The use of CRISPR\/Cas9 as a tool to study human infectious viruses","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0240","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.molmed.2022.06.002_bb0245","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.antiviral.2017.11.006","article-title":"APOBEC3B edits HBV DNA and inhibits HBV replication during reverse transcription","volume":"149","author":"Chen","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.molmed.2022.06.002_bb0250","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/QCO.0b013e3282fe1bb2","article-title":"Hepatitis B: modern concepts in pathogenesis \u2013 APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus","volume":"21","author":"Bonvin","year":"2008","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.molmed.2022.06.002_bb0255","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/hep.21187","article-title":"Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication","volume":"43","author":"Bonvin","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2022.06.002_bb0260","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","article-title":"Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor","volume":"531","author":"Decorsiere","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2022.06.002_bb0265","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2011.02.015","article-title":"Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection","volume":"55","author":"Lucifora","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0270","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.celrep.2016.08.026","article-title":"Hepatitis B virus X protein promotes degradation of SMC5\/6 to enhance HBV replication","volume":"16","author":"Murphy","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2022.06.002_bb0275","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jcmgh.2018.10.010","article-title":"Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction","volume":"7","author":"Sekiba","year":"2019","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0280","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrm3919","article-title":"Protein neddylation: beyond cullin-RING ligases","volume":"16","author":"Enchev","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0285","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2022.06.002_bb0290","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/hep.30491","article-title":"Pevonedistat, a neuronal precursor cell expressed developmentally down-regulated protein 8-activating enzyme inhibitor, is a potent Inhibitor of hepatitis B virus","volume":"69","author":"Sekiba","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2022.06.002_bb0295","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2020.09.019","article-title":"Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx","volume":"74","author":"Cheng","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2022.06.002_bb0300","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.1021\/acs.jmedchem.8b01245","article-title":"Discovery of RG7834: the first-in-class selective and orally available small molecule hepatitis B virus expression inhibitor with novel mechanism of action","volume":"61","author":"Han","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2022.06.002_bb0305","article-title":"The dihydroquinolizinone compound RG7834 Inhibits the polyadenylase function of PAPD5 and PAPD7 and accelerates the degradation of matured hepatitis B virus surface protein mRNA","volume":"65","author":"Sun","year":"2021","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491422001575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491422001575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:25:01Z","timestamp":1761463501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491422001575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1471491422001575"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2022.06.002","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New strategies for the treatment of chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2022.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}